A Post-marketing Surveillance to Assess Safety and Efficacy of Telostop Plus Tab.
Launched by ILDONG PHARMACEUTICAL CO LTD · Aug 23, 2018
Trial Information
Current as of August 02, 2025
Unknown status
Keywords
ClinConnect Summary
This study will collect clinical data, mainly focused on safety, in Korean population as per the requirement of MFDS for market authorization.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • The patient who is first prescribed and administered Telostop plus Tab.
- Exclusion Criteria:
- • The patients who are overreacting to this drug or its components
- • The patients with severe renal impairment
About Ildong Pharmaceutical Co Ltd
Ildong Pharmaceutical Co., Ltd. is a leading South Korean biopharmaceutical company dedicated to the research, development, manufacturing, and marketing of innovative therapeutic solutions. Established in 1941, Ildong has built a strong portfolio across various therapeutic areas, including oncology, neurology, and rare diseases, while prioritizing the advancement of healthcare through cutting-edge research and strategic partnerships. With a commitment to quality and patient-centric approaches, Ildong Pharmaceutical aims to enhance global health outcomes and expand its presence in international markets through robust clinical trials and the development of novel pharmaceuticals.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials